Results from the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) trial will be presented at 2:15 p.m. Sunday in W-3001 (West, Level 3). Itamar Raz, MD, the study’s co-principal investigator, discusses the study’s significance.
Join us in San Diego for the 83rd Scientific Sessions! Registration is now open.
Results from the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) trial will be presented at 2:15 p.m. Sunday in W-3001 (West, Level 3). Itamar Raz, MD, the study’s co-principal investigator, discusses the study’s significance.
